Abviris Deutschland GmbH, an Ammersbek near Hamburg, Germany-based biotech company that has developed a test for the early detection of mouth and throat cancer, raised a mid six-figure funding round.
The company intends to use the funds for a nationwide roll-out of the diagnostic tool as well as international expansion.
Co-founded in 2014 by Dr. Ralf Hilfrich and Stefan Raupach, Abviris develops an assay that allows the early diagnosis of HPV-induced mouth and throat cancer and enables less invasive treatments. Launched in 2015 in Germany, the company distributes the test to dentists, dermatologists and other specialists, who offer cancer prevention services to their patients.
In preparation for the integration of the test into a nationwide screening program, the assay is currently evaluated in the Hamburg City Health Study (HCHS), which represents the largest local medical study worldwide and includes a cohort of 45.000 patients in the age of 45 to 74 years.
The examinations started in 2015 and will be completed in 2020.